Co-Inventors
Taylor, Geraldine
Kwong, Peter
Zhang, Baoshan
Corti, Davide
Lanzavecchia, Antonio
Applications
Vaccines
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Respiratory
Pulmonology
Infectious Disease
Immunology
Research Products
Plasmids/Vectors
Antibodies
Animal Models
The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides. The altered vaccine has shown a marked increase in neutralizing titers in calves, demonstrating an immune response over 100 times greater than those elicited by post-fusion F protein-targeted vaccines. Recognized by prefusion-specific antibodies, such as AM14, D25, and MPE8, this refined vaccine formulation holds the potential to mitigate risks associated with live and attenuated vaccines, which can enhance disease if administered amid an active RSV infection. The technology is poised to not only elevate the standard of bRSV prevention in bovine populations but also has implications for human RSV vaccine development, showcasing a promising avenue for cross-species vaccine research and development.
Commercial Applications
The DS2-stabilized bovine RSV F vaccine has a range of promising potential applications. Primarily, it is positioned to significantly improve the prophylactic measures against bRSV in cattle, an area of substantial economic importance to the livestock industry due to the high morbidity associated with the virus. Beyond veterinary applications, the technology has implications for human RSV vaccine development, as the prefusion-stabilized F protein can potentially elicit stronger immune responses in humans. This innovation could lead to the development of more effective RSV vaccines for high-risk populations, such as infants and the elderly. Furthermore, the platform technology underlying this vaccine could be adapted to target other respiratory viruses in both animals and humans, indicating its versatile application in the broader field of vaccine research. Additionally, the method of stabilization may inform vaccine design principles that can be applied to emerging infectious diseases, thus enhancing global health security.
Competitive Advantages
The novel DS2-stabilized bovine RSV F vaccine offers a suite of competitive advantages over existing RSV vaccines. Firstly, the prefusion stabilization of the F protein significantly increases the vaccine’s immunogenicity, eliciting a neutralizing response far superior to traditional post-fusion protein vaccines. Secondly, it addresses the challenge of maternal antibody interference, which can neutralize live vaccines, thereby providing effective immunity even in the presence of maternal antibodies. Thirdly, the DS2 vaccine minimizes the risk of vaccine-enhanced disease, a critical safety concern with live vaccines. Lastly, its innovative design may offer broader protection by effectively targeting the conserved prefusion conformation of the F protein, potentially offering cross-protection against diverse RSV strains. This pioneering approach is set to not only transform bRSV prevention strategies in calves but also has potential applications in developing more efficacious human RSV vaccines, placing it at the forefront of vaccine research.
